Summit Therapeutics Inc (NASDAQ: SMMT) has seen a decline in its stock price by -8.39 in relation to its previous close of 18.17. However, the company has experienced a -4.69% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-13 that This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
Moreover, the 36-month beta value for SMMT is -0.87. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SMMT is 114.59M and currently, short sellers hold a 17.40% of that float. On January 15, 2025, SMMT’s average trading volume was 2.17M shares.
SMMT’s Market Performance
SMMT stock saw a decrease of -4.69% in the past week, with a monthly decline of -11.29% and a quarterly a decrease of -16.54%. The volatility ratio for the week is 9.08%, and the volatility levels for the last 30 days are 6.78% for Summit Therapeutics Inc (SMMT). The simple moving average for the last 20 days is -8.25% for SMMT stock, with a simple moving average of 26.92% for the last 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Truist repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Truist is $35 based on the research report published on January 08, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see SMMT reach a price target of $30. The rating they have provided for SMMT stocks is “Overweight” according to the report published on December 11th, 2024.
Jefferies gave a rating of “Buy” to SMMT, setting the target price at $31 in the report published on December 06th of the previous year.
SMMT Trading at -11.25% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.87% of loss for the given period.
Volatility was left at 6.78%, however, over the last 30 days, the volatility rate increased by 9.08%, as shares sank -6.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.72% lower at present.
During the last 5 trading sessions, SMMT fell by -4.69%, which changed the moving average for the period of 200-days by +344.00% in comparison to the 20-day moving average, which settled at $18.15. In addition, Summit Therapeutics Inc saw -6.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 54,321 shares at the price of $3.72 back on Mar 27 ’24. After this action, Zanganeh Mahkam now owns 24,923,800 shares of Summit Therapeutics Inc, valued at $201,874 using the latest closing price.
Zanganeh Mahkam, the Chief Executive Officer of Summit Therapeutics Inc, purchase 30,000 shares at $3.75 during a trade that took place back on Mar 26 ’24, which means that Zanganeh Mahkam is holding 30,000 shares at $112,500 based on the most recent closing price.
Stock Fundamentals for SMMT
Current profitability levels for the company are sitting at:
- 772.26 for the present operating margin
- 3.86 for the gross margin
The net margin for Summit Therapeutics Inc stands at 836.93. The total capital return value is set at -0.41. Equity return is now at value -73.22, with -54.54 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.47. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -15.68.
Currently, EBITDA for the company is 1.0 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of -51963.21. The receivables turnover for the company is -0.36for trailing twelve months and the total asset turnover is -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.31.
Conclusion
To wrap up, the performance of Summit Therapeutics Inc (SMMT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
